It is a very cheap, well-tolerated, and Abiraterone or
In all, 50 patients (49%) had a confirmed PSA response
British Journal of Cancer - Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC)
Dexamethasone was associated with a higher PSA response rate (88% vs 60%–78%) and longer radiographic progression-free survival (26
5 mg daily (AA + D) in mCRPC patients progressing to AA + P
British Journal of Cancer - A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant
Background: Dexamethasone, a synthetic glucocorticoid, has clinical benefit in patients with hormone-refractory prostate cancer (HRPC), but the
Dexamethasone affects prostate cancer cell proliferation